Introduction
The successful identification of the gene that is altered in cystic fibrosis (CF) represents the first example in which a disease gene was cloned on the basis of genetic linkage data.'-' The success of this approach was facilitated by the availability of three-generation families with multiple affected individuals and the availability of objective criteria for diagnosing CF. In the 4 years since the cloning of the CF gene, our understanding of the molecular pathology of CF has emerged with remarkable speed. These advances are reviewed below.
The cystic fibrosis gene
The CF gene, now known as the cystic fibrosis transmembrane conductance regulator (CFTR) gene, is localized on the long arm ofchromosome 7, spans approximately 230 kb of DNA and contains 27 exons.' -' Initial evidence that the CFTR gene was the gene mutated in CF came from DNA sequence analysis of cDNA clones from CF patients. This comparison identified a 3 base-pair deletion in exon 10 which would result in the loss of a phenylalanine residue at position 508 (AF508) in CF but not in normal individuals.2 Since then, over 300 CFTR gene mutations have been detected (Cystic Fibrosis Genetic Analysis Consortium, unpublished). These consist of missense, stopcodon, frameshift and splice site mutations that occur throughout the gene. Missense mutations represent 55% of mutations identified so far, while the remainder of mutations are accounted for by nonsense, frameshift and splicing mutations. A single large deletion, deleting exons 4-7 and 9-13 has been identified on a Spanish CF chromosome;5 otherwise, no other gross deletions have been reported, which is surprising for a gene of this size. The distribution of these mutations within the CFTR gene is relatively symmetrical, with the majority occurring in exons 4, 7, 11, 13, 17b and 19. The frequency of the AF508 mutation differs significantly among various ethnic groups, being highest in Denmark and lowest in Turkey. In Northern Europe, the overall frequency is approximately 71%, while in Southern Europe it varies from 45%-55%.6 Why this mutation should be so frequent among Caucasians is unclear. Heterozygote advantage in the form of resistance against enterotoxin-elicited diarrhoeas, or genetic drift represent the most likely explanations. The overall frequency world-wide of mutations other than the AF508 mutation is extremely low. Some ofthese rare alleles segregate with specific ethnic groups. For example, the W1282X mutation accounts for 48% of CF chromosomes in the Ashkenazi Jewish population, and the 621 + lG-*T mutation for 23% of French Canadian CF chromosomes.78 Knowledge of the ethnic distribution of CFTR mutations is therefore essential for prenatal diagnosis and heterozygote screening.
Structure and function of CFTR protein
The CFTR coding region encodes a 1,500 aminoacid protein that shares sequence homology with a superfamily ofproteins involved in the transport of molecules across membranes.2 CFTR contains two repeated motifs, each containing a membrane spanning domain and a hydrophilic nucleotide binding domain (NBD). These two motifs are separated by a highly charged cytoplasmic domain, named the regulatory, or R domain.2 The transmembrane domains and the nucleotide binding folds are shared by all members of this superfamily of proteins, whilst the R domain is unique to CFTR.2 Cross-species analysis of the DNA sequence encoding CFTR shows significant conservation in structure between the human CFTR cDNA and its bovine, mouse, rat and the dogshark homologues, suggesting that the function of CFTR is conserved throughout evolution. 9 The most consistent biochemical defect in CF epithelial cells is a marked reduction in the permeability of chloride (Cl-) ions across their apical membrane.'" Is CFTR a chloride channel, or is it a transport protein involved in the delivery of chloride channels to the apical membrane of epithelial cells? There is now little doubt that CFTR is a chloride channel. Three lines ofevidence support this assertion. First, transfection of nonepithelial cell lines, which do not normally express CFTR, with the normal CFTR cDNA resulted in a plasma membrane chloride conductance that was stimualted by cAMP." Secondly, certain mutations within the transmembrane region of the CFTR protein alter the interanionic selectivity of the channel without affecting its regulation.'2 Finally, reconstitution of purified CFTR into a lipid bilayer induced chloride channels with the correct properties. '3 CFTR may have functions other than those of a small conductance chloride channel in the apical membrane of epithelial cells. A defect in endocytosis and exocytosis was demonstrated in a CF pancreatic cell line (CFPAC), which was corrected by the expression of wild-type CFTR.'4 Membrane recycling regulates the secretion and localization of proteins through and on the cell membrane. A defect in this process may have diverse effects and could explain abnormalities in sodium transport and in the sialylation and sulphation of glycoproteins that are also found in CF. CF cells may also display a defect in the acidification of the trans-Golgi network, of prelysosomes and of endosomes because ofdiminished chloride conductance in the membrane of these intracellular organelles."' However, it is unclear if this chloride conductance is directly mediated by CFTR.
The relationship between CFTR and other epithelial chloride channels is unclear. Observations from the study of 'knockout' mice lacking CFTR suggest that CFTR regulates the function of another distinct protein, the outward rectifying chloride channel.'6 Comparison of the cell-specific expression of CFTR and the multi-drug resistance P-glycoprotein, a putative volume-regulated chloride channel with significant structural homology to CFTR, found that both genes have a complementary pattern ofexpression in all tissues studied. This led to the hypothesis that CFTR and Pglycoprotein serve similar roles in epithelial cells. " There is conflicting evidence in favour of this form of treatment: amiloride has been shown to improve mucociliary clearance in one study,3' but to have no effect in another.32 Similarly, the only two clinical trials give different answers; the first showed a benefit when all other respiratory treatment had been withdrawn,33 while the second showed no benefit from giving amiloride as an additional treatment. 32 Larger studies are under way.
Anti-inflammatory agents
The airways in CF are colonized by bacteria, chiefly Staphylococcus aureus and Pseudomonas aeruginosa. Initially, these remain in the airway lumen with little in the way of tissue invasion and inflammation. Over the years the number of organisms increases as does the inflammatory host response to their presence. It is probably this inflammation which causes the lung damage and a number of anti-inflammatory strategies are being developed. These include anti-proteinases ( The most difficult problem is the shortage of donor organs, and there will never be enough to satisfy the needs of all people dying from respiratory failure. Research is, therefore, continuing into the possible use of animal organs for human transplantation.
Clinical trials
Even without these new treatments the outlook for a child born with CF has never been better, with an estimated life expectancy of40. Existing treatments are effective and with the increasing use of home care systems it is becoming more and more possible for someone with CF to lead a relatively normal life. Against this background of improved prognosis there are some special problems in evaluating all these promising new approaches in clinical trials. In the first place there may be too many phase 3 trials competing for a limited number of suitable patients. Second, the very slow rate of progress of CF lung disease makes the value of any new treatment very difficult to prove without a very long period of study. Third, some new treatments (for example, gene therapy) may be most appropriate for presymptomatic disease and so raise difficult ethical problems. Finally, one of the chief priorities of CF patients may be for a new treatment to replace their existing regimen rather than an addition. These factors will combine to provide new and special challenges for the design of CF clinical trials in the future.
